These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19408809)

  • 1. Bisphosphonates in periodontal treatment: a review.
    Badran Z; Kraehenmann MA; Guicheux J; Soueidan A
    Oral Health Prev Dent; 2009; 7(1):3-12. PubMed ID: 19408809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats.
    Goya JA; Paez HA; Mandalunis PM
    J Periodontol; 2006 Jan; 77(1):1-6. PubMed ID: 16579696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of locally administered tiludronic acid on experimental periodontitis in rats.
    Furlaneto FA; Nunes NL; Oliveira Filho IL; Frota NP; Yamamoto KO; Lisboa MR; Ervolino E; Taba M; Rêgo RO; Messora MR
    J Periodontol; 2014 Sep; 85(9):1291-301. PubMed ID: 24502611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats.
    Menezes AM; Rocha FA; Chaves HV; Carvalho CB; Ribeiro RA; Brito GA
    J Periodontol; 2005 Nov; 76(11):1901-9. PubMed ID: 16274309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral osteoporosis: a review and its dental implications].
    Inagaki K; Kurosu Y; Sakano M; Yamamoto G; Kikuchi T; Noguchi T; Yano H; Izawa H; Hachiya Y
    Clin Calcium; 2007 Feb; 17(2):157-63. PubMed ID: 17272871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of bisphosphonates for periodontitis].
    Shinoda H; Takeyama S
    Clin Calcium; 2006 Feb; 16(2):341- 47. PubMed ID: 16465039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the effects of a novel vacuolar adenosine 5'-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats.
    Niikura K
    J Periodontol; 2006 Jul; 77(7):1211-6. PubMed ID: 16805684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis.
    Braun E; Iacono VJ
    Int J Periodontics Restorative Dent; 2006 Aug; 26(4):315-9. PubMed ID: 16939012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
    Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T
    Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of bisphosphonates.
    Cremers S; Drake MT; Ebetino FH; Bilezikian JP; Russell RGG
    Br J Clin Pharmacol; 2019 Jun; 85(6):1052-1062. PubMed ID: 30650219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
    Drake MT; Cremers SC
    Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host modulation as a therapeutic strategy in the treatment of periodontal disease.
    Kornman KS
    Clin Infect Dis; 1999 Mar; 28(3):520-6. PubMed ID: 10194070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
    Verron E; Bouler JM
    Drug Discov Today; 2014 Mar; 19(3):312-9. PubMed ID: 23974069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis.
    Jeffcoat MK; Cizza G; Shih WJ; Genco R; Lombardi A
    J Int Acad Periodontol; 2007 Jul; 9(3):70-6. PubMed ID: 17715838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic management of periodontal diseases using systemically administered agents.
    Mariotti A; Monroe PJ
    Dent Clin North Am; 1998 Apr; 42(2):245-62. PubMed ID: 9597336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review.
    Reddy MS; Geurs NC; Gunsolley JC
    Ann Periodontol; 2003 Dec; 8(1):12-37. PubMed ID: 14971246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.